It has to be a fishing expedition when there appears something fishy. And we are very close to data, so I am a bit on the edge seeing unnecessary news (instead of data) making us have to figure out what is happening.
Examples:
1. CFO sale of shares
2. Final conference call before data (and its announcement) peculiarly de-emphasizing the covid trials and pointing to the many other indications. Proactive article talks about "even coronavirus". When shareholders are entirely focused on cd12, why this kind of pointing to elsewhere and everywhere?
Am ok with 1 and 2 at this point.
3. The recent proactive video getting removed by proactive and the link thereafter from Cytodyn site. Why in the world? This is unusual behavior. Anything to do with bad cd12 results?
Thankfully that is negated since they brought out an edited version that kept the cd12 parts of the discussion.
4. Now Dr. Kelly's wife filing a form 144 on Feb 1 with intent to sell. She is not just another investor. Management has to know the impact of such a form just before data release. Imagine ten others from BOD and relations also file the form on Feb 1 and investors get this info on Feb 5. Wouldn't that be concerning? That is bad timing even if innocently done or just by her. I can understand she may be taking caution in case the results don't pan out; but she is practically an insider and doing such things at this time is suspect.
Here I assume that in "approx date of sale", the word approx is indicative of intent and not execution. Secondly if she does sell, assuming Cytodyn will not play games to delay info and would file a form 4 on the day of execution.
5. Dr. Kelly exercising warrants. That is fine; there was the deadline next week. However it is still news that we have to wish was not there. If he bought the shares at $0.75 and held them, that shows confidence. If he bought and sold at market price right away, then that may be him being smart with risk and reward and taking some profits. Not sure if he sold or warrant exercise requires immediate sale at market price. But again an insider doing any sort of sale or intent right before data release is bad timing and poor management. IMO. (Just as insider doing Buys or showing intent would be positive indication before data release.)
We have to ask questions and consider possibilities. I am however ok with Scooter's post #144973 on this issue. At this point we are invested based on fundamentals, doctors' reports, anecdotal data, NEWS2, the pandemic situation etc. and barring very obvious info to the contrary, cannot throw overboard the original basis for our investment. Accept the outcome and wait for results, or lower risk or get out now; won't know right or wrong till data release.
